#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Spinal cord injury cervical Aplastic anaemia Hepatic angiosarcoma Primary biliary cholangitis Juvenile psoriatic arthritis Factor IX deficiency Acute myeloid leukaemia (in remission) Fibrosarcoma metastatic Paget's disease of the vulva Philadelphia positive acute lymphocytic leukaemia Haemophilia B without inhibitors Thrombocytopenia Rhabdomyosarcoma Paraneoplastic neurological syndrome Keratosis follicular More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia – Diagnostics Focal segmental glomerulosclerosis – Diagnostics Marfan’s syndrome – Trials in Disease Pemphigus Osteosarcoma – Trials in Disease Mantle cell lymphoma Glomerulonephritis rapidly progressive Bronchopulmonary dysplasia Acute respiratory distress syndrome – Basic Information Glomerulonephritis rapidly progressive – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Metoprolol Tartrate Db-Oto-5 Citicoline Sodium Bulevirtide Murcidencel Mocravimod Tulmimetostat Ab-1002 Baloxavir Marboxil Daunorubicin Hydrochloride Argatroban Monohydrate AZD4512 DIMENHYDRINATE Mitomycin Isis 678354 Sodium Salt Erdafitinib Ascorbic Acid Bp Sqy51 Skb264 INCB123667 More therapies…

    Learn about Your Condition

    Bone hypertrophy Naevus flammeus Epilepsy Hereditary ataxia Hepatic fibrosis Dermatitis atopic Acquired haemophilia Peritoneal sarcoma Polyneuropathy Muscle spasticity Spina bifida Dizziness Acute leukaemia Epileptic encephalopathy Sjogren's syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    • Darolutamide
    Austria Belgium Finland France Germany Hungary +5

  • Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Trabectedin
    • Mitotane
    • Calcium Folinate
    France

  • Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anhydrous Cyclophosphamide
    • D,L-Lysine Acetylsalicylate
    • Regorafenib
    France

  • Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Relatlimab
    • Ipilimumab
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium France Germany Italy Poland +1

  • Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Abiraterone Acetate
    • Gozetotide
    Belgium France Ireland Italy The Netherlands Spain

  • Study on Tislelizumab for Cancer Patients with Molecular Residual Disease After Standard Treatment

    Recruiting

    3 1 1
    Investigated Drugs:
    • Tislelizumab
    • Sodium Chloride
    France

  • Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Ipilimumab
    • Cabozantinib
    Austria Belgium Czechia Denmark Finland France +4

  • Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    France

  • Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Giredestrant
    • Inavolisib
    • Abemaciclib
    France Greece Italy Spain

  • Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

    Recruiting

    2 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Endometrial cancer
    • Breast cancer
    Investigated Drugs:
    • Pc14586
    France Germany Italy Spain
Previous Page
1 … 4 5 6 7 8 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!